From revolutionary science to the impact of Obamacare, every week The Motley Fool's health care team sits down to discuss the most fascinating developments across the health care industry and their implications for long-term investors. In this week's edition, the team talks about the disruptive potential of a new iPhone app, as well as an FDA inquiry that could have negative implications for some of the pharmaceutical industry's biggest players. In addition, our analysts dive into some of the stocks making big moves over the past week and discuss companies on their radar for the near future.
In this segment, health care bureau chief Brenton Flynn discusses AstraZeneca, which only minutes prior to the show's filming had released some key strategic priorities to reinvigorate the company. Is this high-yielding dividend stock moving in the right direction? Follow along in the video below to learn more.
But first, if you're on the lookout for high-yielding stocks, The Motley Fool has compiled a special free report outlining our nine top dependable dividend-paying stocks. It's called "Secure Your Future With 9 Rock-Solid Dividend Stocks." You can access your copy today at no cost! Just click here.
The relevant video segment can be found between 16:11 and 18:05.
The article The Future of AstraZeneca, Pharma's Biggest Dividend originally appeared on Fool.com.Brenton Flynn, David Williamson, Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.